• BioTime is a late stage clinical
    biotechnology company focused
    on degenerative diseases

About Us:

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors:

  • Aesthetics
  • Ophthalmology
  • Cell/drug delivery

Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery.

  • Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® is expected later this year, with an anticipated commercial launch in 2018.
  • OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries.

BioTime also has significant equity holdings in two publicly traded companies and one private company:

  • Asterias Biotherapeutics, Inc. (NYSE American: AST)
  • OncoCyte Corporation (NYSE American: OCX)
  • AgeX Therapeutics, Inc.

BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on  Twitter, LinkedIn, Facebook, YouTube, and  Google+.

Latest News

More News


More Events